Rapid improvement of psychiatric stigmata after IFN-free treatment in HCV patients with and without cryoglobulinemic vasculitis.
Laura GragnaniSerena LoriniLorenzo MartiniCristina StasiMarcella VisentiniLuisa PetracciaNiccolò MarelloMonica MontiSilvia MarriFrancesco MadiaValdo RiccaAnna Linda ZignegoPublished in: Clinical rheumatology (2021)
After HCV eradication, the depression and anxiety scores significantly improved and severity grade generally lowered. DAA-positive effects on mental disorders should be considered part of the therapy outcome, being beneficial especially in CV patients who usually have worse baseline mental scores. Key Points • HCV frequently causes psychiatric disorders and an often-invalidating autoimmune/lymphoproliferative disease called cryoglobulinemic vasculitis. • The new direct acting antivirals (DAAs) are very effective and well tolerated by HCV-patients. • This study shows DAA-induced benefits on depression and anxiety in HCV-patients that are especially evident in CV patients who usually have worse baseline mental scores. • DAA-induced benefits are observed in the short-term post-therapy follow-up, in contrast with data previously obtained in HCV patients treated with IFN-based anti-HCV therapy.
Keyphrases
- hepatitis c virus
- end stage renal disease
- human immunodeficiency virus
- newly diagnosed
- mental health
- immune response
- peritoneal dialysis
- prognostic factors
- magnetic resonance
- magnetic resonance imaging
- drug induced
- bone marrow
- dendritic cells
- patient reported outcomes
- big data
- machine learning
- epstein barr virus
- hiv infected
- cell therapy
- artificial intelligence
- smoking cessation
- diffuse large b cell lymphoma
- endothelial cells
- loop mediated isothermal amplification
- sensitive detection